Utilizing cross-product prior knowledge to rapidly de-risk chemical liabilities in therapeutic antibody candidates
Abstract There is considerable pressure in the pharmaceutical industry to advance better molecules faster. One pervasive concern for protein-based therapeutics is the presence of potential chemical liabilities. We have developed a simple methodology for rapidly de-risking specific chemical concerns...
Saved in:
Main Authors: | Alex W. Jacobitz (Author), Wilfredo Rodezno (Author), Neeraj J. Agrawal (Author) |
---|---|
Format: | Book |
Published: |
SpringerOpen,
2022-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Introduction to Contracts, Sales and Product Liability
by: Mayer, Don, et al.
Published: (2012) -
Utilization of rapid antigen tests for screening SARS-CoV-2 prior to dental treatment
by: Pisha Pittayapat, et al.
Published: (2022) -
Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice
by: Shufang Liu, et al.
Published: (2023) -
Civil liability in pharmacy
by: O. H. Aleksieiev
Published: (2021) -
Economic Effects of Product Liability and Other Litigation Involving the Safety and Effectiveness of Pharmaceuticals
by: Garber, Steven
Published: (2013)